Effective Strategies for Drug Innovators, Managing Generic Competition, the Threat of Drug Reimportation and the Dynamic Political Climate

Plus!
• A review of the FTC’s report “To Promote Innovation: The Proper Balance of Competition and Patent and Policy” and its implication for the pharmaceutical industry.
• Interactive Panels on 505(b)(2) Strategies and the Medicare Reform/Prescription Drug Act

Donald O. Beers
Partner
ARNOLD & PORTER

M. Kenneth Bowler
Vice President, Federal Government Relations & Corporate Affairs
PFIZER

Jeffrey Chasnow
Senior Corporate Counsel
PFIZER
James N. Czaban
Shareholder, FDA Practice Group
HELLER EHRMAN WHITE & MCAULIFFE LLP

Nicholas M. Fleisher, R.Ph., Ph.D.
Vice President, Clinical Pharmacology & Biopharmaceutics
THE WEINBERG GROUP

Andy Gibbs
President & CEO
PATENTCAFE®

Michael Kades
Attorney
FEDERAL TRADE COMMISSION

Richard F. Kingham
Partner
COVINGTON & BURLING

Kenneth A. Letzler
Partner
ARNOLD & PORTER

Geoffrey Levitt
Vice President & Chief Regulatory Counsel
WYETH PHARMACEUTICALS

J. Christopher Prue, R.Ph., MBA
Senior Director, Regulatory Affairs
PURDUE PHARMA LP

Paul A. Saatsoglou
Practice Leader, Global Portfolio Optimization
IMS HEALTH

Ted Whitlock
Intellectual Property Counsel
ANDRX CORPORATION